See more : BCE Inc. (BCE) Income Statement Analysis – Financial Results
Complete financial analysis of Tekla Life Sciences Investors (HQL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tekla Life Sciences Investors, a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- Smartbroker Holding AG (SB1.DE) Income Statement Analysis – Financial Results
- Smartcool Systems Inc. (SSCFF) Income Statement Analysis – Financial Results
- Eden Research plc (EDEN.L) Income Statement Analysis – Financial Results
- Lifezone Metals Limited (LZM) Income Statement Analysis – Financial Results
- NanoGroup S.A. (NNG.WA) Income Statement Analysis – Financial Results
Tekla Life Sciences Investors (HQL)
About Tekla Life Sciences Investors
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.69M | 23.52M | -103.25M | 65.69M | 124.08M | -69.34M | 29.82M | 69.81M | 6.29M | 1.32M | 876.79K | 516.76K | 2.14M | 570.00K | 1.82M | 460.00K | 1.67M | 2.88M | 2.30M | 890.00K | 320.00K | 610.00K | 940.00K | 1.77M | 140.00K | 320.00K | 420.00K |
| Cost of Revenue | 0.00 | 5.24M | 5.55M | 6.08M | 5.21M | 5.00M | 4.77M | 4.61M | 4.95M | 5.65M | 4.14M | 3.10M | 2.48M | 3.02M | 2.99M | 2.85M | 3.76M | 3.62M | 2.93M | 2.81M | 2.78M | 2.44M | 2.86M | 3.26M | 1.64M | 1.63M | 1.60M |
| Gross Profit | 86.69M | 18.28M | -108.80M | 59.61M | 118.88M | -74.35M | 25.05M | 65.20M | 1.34M | -4.33M | -3.26M | -2.58M | -335.50K | -2.45M | -1.17M | -2.39M | -2.09M | -740.00K | -630.00K | -1.92M | -2.46M | -1.83M | -1.92M | -1.49M | -1.50M | -1.31M | -1.18M |
| Gross Profit Ratio | 100.00% | 77.71% | 105.37% | 90.75% | 95.80% | 107.22% | 84.00% | 93.40% | 21.34% | -327.02% | -372.18% | -499.89% | -15.64% | -429.82% | -64.29% | -519.57% | -125.15% | -25.69% | -27.39% | -215.73% | -768.75% | -300.00% | -204.26% | -84.18% | -1,071.43% | -409.38% | -280.95% |
| Research & Development | 0.00 | 0.00 | -3.28 | 1.43 | 3.15 | -1.84 | 0.80 | 1.46 | -1.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | 5.23M | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | -1.89 | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Other Expenses | 85.35M | 22.62M | 275.97K | 313.69K | 278.66K | 259.76K | 466.64K | 423.33K | 20.74M | 143.44K | 130.00K | 150.00K | 200.00K | 200.00K | 160.00K | 170.00K | 140.00K | 250.00K | 160.00K | 150.00K | 80.00K | 60.00K | 120.00K | 110.00K | 10.00K | 40.00K | 290.00K |
| Operating Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 1.16M | 1.26M | 13.35M | 39.18M | 88.39M | 84.13M | 75.49M | 1.35M | 790.00K | 760.00K | 820.00K | 970.00K | 710.00K | 660.00K | 610.00K | 510.00K | 590.00K | 450.00K | 240.00K | 230.00K | 290.00K |
| Cost & Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 5.59M | 5.56M | 1.34M | 39.18M | 88.39M | 84.13M | 75.49M | 4.37M | 3.78M | 3.61M | 4.58M | 4.59M | 3.64M | 3.47M | 3.39M | 2.95M | 3.45M | 3.71M | 1.88M | 1.86M | 1.89M |
| Interest Income | 1.04M | 204.45K | 50.09K | 0.00 | 164.80K | 216.70K | 90.71K | 90.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.27M | 72.43M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 0.00 | 27.60M | 2.99M | 4.14M | 2.11M | 2.88M | 3.61M | 3.88M | 3.79M | 4.72M | 3.77M | 3.17M | 1.28M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| EBITDA | 0.00 | 22.35M | -104.61M | 64.54M | 123.06M | -70.47M | 28.67M | 68.56M | 0.00 | 0.00 | 0.00 | 0.00 | 78.91M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| EBITDA Ratio | 0.00% | 95.03% | 101.31% | 98.24% | 99.17% | 101.64% | 204.33% | 201.96% | 289.30% | 3,419.13% | 10,610.66% | 16,993.50% | 3,679.80% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Operating Income | 0.00 | -5.24M | -104.60M | 64.53M | 123.05M | -70.48M | -3.61M | -3.88M | -3.79M | -4.72M | -3.77M | -3.17M | -1.28M | -3.80M | -1.96M | -3.15M | -2.92M | -1.71M | -1.34M | -2.59M | -3.07M | -2.34M | -2.52M | -1.94M | -1.75M | -1.53M | -1.47M |
| Operating Income Ratio | 0.00% | -22.29% | 101.31% | 98.24% | 99.17% | 101.64% | -12.10% | -5.56% | -60.25% | -357.04% | -429.50% | -613.43% | -59.85% | -666.67% | -107.69% | -684.78% | -174.85% | -59.38% | -58.26% | -291.01% | -959.38% | -383.61% | -268.09% | -109.60% | -1,250.00% | -478.13% | -350.00% |
| Total Other Income/Expenses | 85.30M | 27.60M | -101.61M | 6.08M | 5.21M | -67.60M | 32.61M | 72.74M | -8.12M | 45.22M | 93.03M | 87.82M | 78.91M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| Income Before Tax | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Income Before Tax Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.33% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Income Tax Expense | 0.00 | 0.00 | -2.99M | -4.15M | -2.13M | -2.88M | 1.00 | 3.00 | 26.32M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Net Income Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.30% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| EPS | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.28 | 3.21 | 1.00 | 2.06 | 4.70 | 5.65 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| EPS Diluted | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.23 | 3.21 | 20.74M | 2.06 | 4.70 | 5.64 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| Weighted Avg Shares Out | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 22.41M | 21.36M | -11.91M | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
| Weighted Avg Shares Out (Dil) | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 23.30M | 21.36M | -0.57 | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
5 Best CEFs This Month For 8.5% Yield (November 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market....
5 Best CEFs This Month For 9.5% Yield (October 2024)
For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For...
5 Best CEFs This Month For 9% Plus Yield (September 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market....
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
PHILADELPHIA, PA / ACCESSWIRE / August 9, 2024 / The following abrdn U.S. Closed-End Funds (NYSE:ACP)(NYSE:ASGI)(NYSE:AWP)(NYSE:HQH)(NYSE:HQL)(NYSE:IFN)(NYSE:JEQ)(NYSE:THQ)(NYSE:THW)(NYSE American:FAX)(NYSE American:FCO)(NYSE American:IAF)(NYSE American:VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per...
Finding Opportunities In The Closed-End Fund World
Closed-end funds have unique features that make them very attractive investment vehicles for the right asset classes and investors who understand them. Especially for complex and/or less liquid asset classes, like corporate senior loans, high-yield bonds, collateralized loan obligations, and...
abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ), and abrdn World Healthcare Fund (THW) Announce Investment Team Update
PHILADELPHIA, PA / ACCESSWIRE / March 21, 2024 / abrdn Healthcare Investors (NYSE:HQH), abrdn Life Sciences Investors (NYSE:HQL), abrdn Healthcare Opportunities Fund (NYSE:THQ), and abrdn World Healthcare Fund (NYSE:THW) (collectively, the "Funds") each, a closed-end management investment company, announced today...
The Month In Closed-End Funds: December 2023
For the second consecutive month, both equity (+3.42% on a NAV basis) and fixed income (+3.14%) CEFs on average posted plus-side returns. At month end, 9% of all CEFs traded at a premium to their NAV, with 9% of equity...
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
PHILADELPHIA, PA / ACCESSWIRE / November 9, 2023 / The following abrdn U.S. Closed-End Funds announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on November 30,...
abrdn Announces Its Appointment to Four U.S. Specialist Healthcare Closed-End Funds, New Board of Trustees to the Funds and Fund Name Changes
PHILADELPHIA, PA / ACCESSWIRE / October 27, 2023 / Effective close of business today, October 27, 2023, abrdn Inc. ("abrdn") assumed responsibility for the management of the four (4) former Tekla Capital Management LLC closed-end funds totaling $2.8bn in assets...
Tekla Funds Approve New Investment Advisory Agreements With abrdn Inc.
BOSTON--(BUSINESS WIRE)--Tekla Capital Management LLC (Tekla) announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn Inc. for each of its four closed-end funds (the Funds). The Funds are: Tekla Healthcare Investors...
Source: https://incomestatements.info
Category: Stock Reports